Similarly, bone-targeted biomimetic nanogels have been developed to treat postmenopausal osteoporosis (PMOP) by scavenging RANKL and responsively releasing therapeutic PTH 1–34 in the bone microenvironment (30). The gene discussed is TNFSF11; the disease is postmenopausal osteoporosis.